Millennium moves colitis trial forward
Millennium's potential treatment for ulcerative colitis, coded LDP-02, has entered into Phase II trials in Canada. The drug is an investigational humanisedmonoclonal antibody for the treatment of inflammatory bowel diseases, including colitis. The drug is also being evaluated as a treatment for Crohn's disease.
The company is collaborating with Genentech over the commercialisation of the treatment. Genentech receives exclusive worldwide marketing rights. Millennium is to develop LDP-02 through Phase II; if these trials are successful then Genentech will complete the product development. At this stage, Millenniumwill have the option to share the development costs in return for a share of profits on US sales, in addition to royalties on non-US sales. Millennium will also receive milestone payments.